Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease.
Aged
Albuminuria
/ drug therapy
Biomarkers
/ blood
Blood Glucose
/ drug effects
Blood Pressure
/ drug effects
Diabetes Mellitus, Type 2
/ diagnosis
Diabetic Nephropathies
/ diagnosis
Female
Glycated Hemoglobin
/ metabolism
Humans
Japan
/ epidemiology
Kidney
/ drug effects
Male
Middle Aged
Renal Insufficiency, Chronic
/ diagnosis
Retrospective Studies
Sodium-Glucose Transporter 2 Inhibitors
/ adverse effects
Time Factors
Treatment Outcome
Journal
Journal of diabetes research
ISSN: 2314-6753
Titre abrégé: J Diabetes Res
Pays: England
ID NLM: 101605237
Informations de publication
Date de publication:
2019
2019
Historique:
received:
09
01
2019
revised:
15
05
2019
accepted:
26
08
2019
entrez:
30
11
2019
pubmed:
30
11
2019
medline:
28
4
2020
Statut:
epublish
Résumé
The renoprotective effect of sodium-glucose cotransporter 2 inhibitors is thought to be due, at least in part, to a decrease in blood pressure. The aim of this study was to determine the renal effects of these inhibitors in low blood pressure patients and the dependence of such effect on blood pressure management status. The subjects of this retrospective study were 740 patients with type 2 diabetes mellitus and chronic kidney disease who had been managed at the clinical facilities of the Kanagawa Physicians Association. Data on blood pressure management status and urinary albumin-creatinine ratio were analyzed before and after treatment. Changes in the logarithmic value of urinary albumin-creatinine ratio in 327 patients with blood pressure < 130/80 mmHg at the initiation of treatment and in 413 patients with BP above 130/80 mmHg were -0.13 ± 1.05 and -0.24 ± 0.97, respectively. However, there was no significant difference between the two groups by analysis of covariance models after adjustment of the logarithmic value of urinary albumin-creatinine ratio at initiation of treatment. Changes in the logarithmic value of urinary albumin-creatinine ratio in patients with mean blood pressure of <102 mmHg ( Our results confirmed that blood pressure management status after treatment with SGLT2 inhibitors influences the extent of change in urinary albumin-creatinine ratio. Stricter blood pressure management is needed to allow the renoprotective effects of sodium-glucose cotransporter 2 inhibitors.
Identifiants
pubmed: 31781668
doi: 10.1155/2019/9415313
pmc: PMC6875192
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Glycated Hemoglobin A
0
Sodium-Glucose Transporter 2 Inhibitors
0
hemoglobin A1c protein, human
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
9415313Informations de copyright
Copyright © 2019 Kazuo Kobayashi et al.
Déclaration de conflit d'intérêts
The author and coauthors declare no conflict of interest associated with this study.
Références
Diabetes Obes Metab. 2016 Jun;18(6):590-7
pubmed: 26936519
N Engl J Med. 2013 Oct 3;369(14):1327-35
pubmed: 23992602
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Diabetologia. 2014 Dec;57(12):2599-602
pubmed: 25280671
Diabetes Care. 2016 Jul;39(7):1108-14
pubmed: 27289126
PLoS One. 2014 Jun 24;9(6):e100777
pubmed: 24960177
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
Hypertens Res. 2014 Apr;37(4):253-390
pubmed: 24705419
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
N Engl J Med. 2013 Oct 3;369(14):1317-26
pubmed: 23992601
Lancet Diabetes Endocrinol. 2017 Aug;5(8):610-621
pubmed: 28666775
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Diabetes Care. 2018 Jan;41(Suppl 1):S86-S104
pubmed: 29222380
Diabetes Metab Rev. 1988 Mar;4(2):163-77
pubmed: 3281808
Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266
pubmed: 11904577
Clin Exp Hypertens. 2019;41(7):637-644
pubmed: 30373408
N Engl J Med. 2015 Jul 16;373(3):232-42
pubmed: 26052984
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Diab Vasc Dis Res. 2019 Jan;16(1):103-107
pubmed: 30284913
Am J Physiol Renal Physiol. 2004 Jan;286(1):F8-15
pubmed: 14656757
Hypertens Res. 2008 Apr;31(4):657-64
pubmed: 18633177
Circulation. 2014 Feb 4;129(5):587-97
pubmed: 24334175